TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$89 Million

uniQure

Follow-on Offering

Bookrunner, April 2015

uniQure NV is a gene therapy company. It develops treatment and platform for patients suffering from genetic and other devastating diseases. Its products and services are focused towards hemophilia, Huntington's disease, and cardiovascular diseases. The company's manufacturing facility is located in Lexington Massachusetts and research and development facility in Amsterdam, the Netherlands, and Heidelberg, Germany. It is focused on the development of pipeline of gene therapies with the collaboration of Bristol Myers-Squibb for cardiovascular diseases.